- Trial phase
- Approved
- Time to market
- Eticovo is already FDA-approved (since 2019) but is blocked from U.S. commercial launch by Amgen's patent injunction until at least 2029. Teva obtains U.S. commercialization rights upon deal close (expected by end of 2026), but cannot generate revenue until the patent barrier lifts.
- Why 4/10
- Eticovo is already FDA-approved (since 2019) with no pending PDUFA or pivotal readout; the next hard catalyst would be its U.S. market launch, which is blocked by Amgen's patent injunction until at least 2029, more than 12 months away. As an approved drug with no imminent binary catalyst at a large diversified pharma company, the impact score is low.
The key event is today's (Nov 3, 2026) deal with Samsung Bioepis giving Teva U.S. commercialization rights to Eticovo upon close. However, Eticovo remains blocked from the U.S. market by Amgen's Enbrel patents until at least 2029, so near-term revenue is zero. Watch for the deal closing (expected by end of 2026) and any patent-litigation developments that could shift the 2029 launch timeline.
Price Chart
Executive Summary
Eticovo (etanercept-ykro) is an FDA-approved biosimilar to Amgen's blockbuster anti-inflammatory drug Enbrel, developed by Samsung Bioepis. On November 3, 2026, Teva announced a deal worth up to $420 million to commercialize Eticovo and another biosimilar (Renflexis) in the U.S. However, Eticovo has been blocked from the U.S. market since its 2019 approval by Amgen's patent litigation, with a permanent injunction preventing launch until at least 2029. For Teva, a large diversified pharma company, this deal adds a long-dated pipeline asset with no near-term revenue contribution.
How It Works
Eticovo is a biosimilar (a near-identical copy) of Enbrel (etanercept), a biologic drug that blocks tumor necrosis factor (TNF), a protein that drives inflammation in autoimmune diseases. By neutralizing TNF, Eticovo reduces inflammation and symptoms in conditions like rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and plaque psoriasis.
Trial Status
Eticovo received FDA approval in 2019 based on a Phase III study demonstrating comparable efficacy and safety to the reference product Enbrel (etanercept). It is approved for rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, and plaque psoriasis but has not been commercially launched in the U.S. due to patent litigation.
The Two-Sided Case
Upcoming Catalysts
- Closing of the Samsung Bioepis commercialization deal (expected by end of 2026)
- U.S. market entry for infliximab-abda (Renflexis biosimilar) in Q3 2027 (the second product in the deal)
- Any patent-litigation developments that could shift the 2029 U.S. launch timeline for Eticovo
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Teva Pharmaceutical Industries Ltd Press Release TEVA ·Originating report